CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
CORMEDIX INC. TO PRESENT AT THE CANTOR GLOBAL HEALTHCARE CONFERENCE
September 13, 2024
2024年9月13日
Berkeley Heights, NJ – September 13, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be participating in a fireside chat and investor meetings at the 2024 Cantor Healthcare Conference, being held in New York, NY on September 17 – 19, 2024.
新泽西州伯克利高地——2024年9月13日——专注于开发和商业化用于预防和治疗危及生命的疾病的治疗产品的生物制药公司CorMedix公司（纳斯达克股票代码：CRMD）今天宣布，管理层将参加2024年9月17日至19日在纽约州纽约举行的2024年坎托医疗会议的炉边谈话和投资者会议。
Cantor Global Healthcare Conference
Date: Thursday, September 19, 2024
Time: 10:55AM EDT
Format: Fireside Chat and 1×1 Meetings
Webcast: Click Link
Cantor 全球医疗保健会议
日期：2024 年 9 月 19 日星期四
时间：美国东部时间上午 10:55
形式：炉边聊天和 1×1 会议
网络直播：点击链接
A replay of the fireside chat will also be available in the "Events and Presentations" page on the investor relations portion of the Company's website at:
炉边谈话的重播也将在公司网站投资者关系部分的 “活动和演讲” 页面上播出，网址为：
About CorMedix
关于 Cormedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: .
CormediX Inc. 是一家生物制药公司，专注于开发和商业化治疗产品，用于预防和治疗危及生命的疾病和疾病。该公司专注于将其主要产品DefenCath商业化，该产品于2023年11月15日获得美国食品药品管理局的批准。CorMedix 于 2024 年 4 月在住院环境中商业推出 DefenCath，并于 2024 年 7 月在门诊环境中推出。CorMedix还打算开发DefenCath作为导管锁解决方案，用于其他患者群体。欲了解更多信息，请访问:.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投资者联系人：
丹·费里
董事总经理
生命科学顾问
daniel@lifesciadvisors.com
(617) 430-7576